New users of SGLT-2 inhibitors were younger (56.2 vs 65.3 years) and more unlikely to have severe diabetes (1.1 vs 1.4 scores) and comorbidities of cerebrovascular disease (7.0% vs 12.8%), hypertension (65.6% vs 72.7%), nephropathy (8.2% vs 16.9%), and renal disease (8.4% vs 17.6%) compared with new users of DPP-4 inhibitors. The gene discussed is DPP4; the disease is diabetes mellitus.